- NEWS FEATURE
The race for antiviral drugs to beat COVID — and the next pandemic
Illustration by David Parkins
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 592, 340-343 (2021)
doi: https://doi.org/10.1038/d41586-021-00958-4
References
Knobler, S. et al. (eds) Learning from SARS: Preparing for the Next Disease Outbreak: Workshop Summary (National Academies Press, 2004).
Sheahan, T. P. et al. Sci. Transl. Med. 9, eaal3653 (2017).
Beigel, J. H. et al. N. Engl. J. Med. 383, 1813–1826 (2020).
WHO Solidarity Trial Consortium N. Engl. J. Med. 384, 497–511 (2021).
Sheahan, T. P. et al. Sci. Transl. Med. 12, eabb5883 (2020).
Sender, R. et al. Preprint at medRxiv https://doi.org/10.1101/2020.11.16.20232009 (2020).
Jackman, J. A. et al. Nature Mater. 17, 971–977 (2018).
Hoffman, R. L. et al. J. Med. Chem. 63, 12725–12747 (2020).
Boras, B. et al. Preprint at bioRxiv https://doi.org/10.1101/2020.09.12.293498 (2021).
Funders, now is the time to invest big in COVID drugs
What scientists do and don’t know about the Oxford–AstraZeneca COVID vaccine
How COVID unlocked the power of RNA vaccines
COVID antibody treatments show promise for preventing severe disease
Latin America’s embrace of an unproven COVID treatment is hindering drug trials
